Deptartment of Gastroenterology, Campbelltown Hospital, Campbelltown, NSW 2560, Australia.
School of Medicine and Public Health, University of Newcastle, Newcastle, NSW 2308, Australia.
Medicina (Kaunas). 2024 Jan 6;60(1):108. doi: 10.3390/medicina60010108.
Slow transit constipation (STC) has an estimated prevalence of 2-4% of the general population, and although it is the least prevalent of the chronic constipation phenotypes, it more commonly causes refractory symptoms and is associated with significant psychosocial stress, poor quality of life, and high healthcare costs. This review provides an overview of the pathophysiology, diagnosis, and management options in STC. STC occurs due to colonic dysmotility and is thought to be a neuromuscular disorder of the colon. Several pathophysiologic features have been observed in STC, including reduced contractions on manometry, delayed emptying on transit studies, reduced numbers of interstitial cells of Cajal on histology, and reduced amounts of excitatory neurotransmitters within myenteric plexuses. The underlying aetiology is uncertain, but autoimmune and hormonal mechanisms have been hypothesised. Diagnosing STC may be challenging, and there is substantial overlap with the other clinical constipation phenotypes. Prior to making a diagnosis of STC, other primary constipation phenotypes and secondary causes of constipation need to be ruled out. An assessment of colonic transit time is required for the diagnosis and can be performed by a number of different methods. There are several different management options for constipation, including lifestyle, dietary, pharmacologic, interventional, and surgical. The effectiveness of the available therapies in STC differs from that of the other constipation phenotypes, and prokinetics often make up the mainstay for those who fail standard laxatives. There are few available management options for patients with medically refractory STC, but patients may respond well to surgical intervention. STC is a common condition associated with a significant burden of disease. It can present a clinical challenge, but a structured approach to the diagnosis and management can be of great value to the clinician. There are many therapeutic options available, with some having more benefits than others.
慢传输型便秘(STC)在普通人群中的估计患病率为 2-4%,尽管它是慢性便秘表型中最不常见的一种,但它更常引起难治性症状,并与显著的心理社会压力、生活质量差和高医疗保健费用相关。本综述介绍了 STC 的病理生理学、诊断和治疗选择。STC 是由于结肠动力障碍引起的,被认为是一种结肠的神经肌肉疾病。在 STC 中观察到了几种病理生理特征,包括测压时收缩减少、传输研究时排空延迟、组织学上 Cajal 间质细胞数量减少以及肠肌丛内兴奋性神经递质减少。其潜在病因尚不确定,但已假设存在自身免疫和激素机制。诊断 STC 可能具有挑战性,并且与其他临床便秘表型有很大的重叠。在做出 STC 的诊断之前,需要排除其他原发性便秘表型和继发性便秘的原因。结肠传输时间的评估是诊断所必需的,可以通过多种不同的方法进行。便秘有几种不同的治疗选择,包括生活方式、饮食、药物、介入和手术。现有的治疗方法在 STC 中的有效性与其他便秘表型不同,促动力药通常是对标准泻药治疗失败的主要治疗方法。对于患有医学难治性 STC 的患者,可用的治疗方法很少,但患者可能对手术干预反应良好。STC 是一种常见的疾病,与疾病负担有很大关系。它可能会带来临床挑战,但对诊断和治疗的结构化方法对临床医生非常有价值。有许多治疗选择,其中一些比其他的更有优势。